Brokers Offer Predictions for SRTS FY2028 Earnings

Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) - Roth Capital issued their FY2028 earnings per share (EPS) estimates for Sensus Healthcare in a research note issued on Thursday, February 6th. Roth Capital analyst J. Wittes expects that the company will earn $0.30 per share for the year. The consensus estimate for Sensus Healthcare's current full-year earnings is $0.71 per share. Roth Capital also issued estimates for Sensus Healthcare's FY2029 earnings at $0.34 EPS.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.09 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%.

SRTS has been the subject of a number of other reports. Lake Street Capital initiated coverage on Sensus Healthcare in a research note on Friday, January 31st. They set a "buy" rating and a $18.00 price target for the company. Maxim Group raised their target price on Sensus Healthcare from $12.00 to $14.00 and gave the company a "buy" rating in a research note on Friday, November 15th. Finally, HC Wainwright boosted their price target on shares of Sensus Healthcare from $11.00 to $12.00 and gave the stock a "buy" rating in a research report on Monday.

Sensus Healthcare Price Performance

Shares of NASDAQ SRTS traded down $0.15 during mid-day trading on Monday, reaching $5.50. 305,901 shares of the company traded hands, compared to its average volume of 434,328. Sensus Healthcare has a fifty-two week low of $2.91 and a fifty-two week high of $9.33. The firm has a market cap of $90.15 million, a PE ratio of 13.75 and a beta of 1.24. The stock has a fifty day simple moving average of $7.22 and a 200-day simple moving average of $6.88.

Hedge Funds Weigh In On Sensus Healthcare

A number of hedge funds have recently modified their holdings of SRTS. Renaissance Technologies LLC lifted its position in shares of Sensus Healthcare by 5.3% in the 4th quarter. Renaissance Technologies LLC now owns 430,934 shares of the company's stock valued at $2,982,000 after acquiring an additional 21,600 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Sensus Healthcare by 128.0% during the second quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company's stock valued at $888,000 after buying an additional 93,511 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in Sensus Healthcare by 81.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company's stock valued at $1,039,000 after buying an additional 67,269 shares during the period. Geode Capital Management LLC lifted its stake in Sensus Healthcare by 8.5% in the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company's stock worth $849,000 after acquiring an additional 11,525 shares in the last quarter. Finally, Marshall Wace LLP boosted its position in Sensus Healthcare by 99.6% during the 4th quarter. Marshall Wace LLP now owns 132,286 shares of the company's stock worth $915,000 after acquiring an additional 65,994 shares during the period. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.